Literature DB >> 1681782

Dopa-responsive dystonia: [18F]dopa positron emission tomography.

G V Sawle1, K L Leenders, D J Brooks, G Harwood, A J Lees, R S Frackowiak, C D Marsden.   

Abstract

The syndrome of dopa-responsive dystonia comprises a minority of patients with dystonia, yet it is of considerable diagnostic importance because patients respond dramatically to L-dopa therapy. Benefits from this treatment are lasting, and the problems associated with long-term L-dopa therapy in patients with Parkinson's disease are generally absent. It has been suggested that this condition is due to a defect in the dopamine synthetic pathway, which is bypassed when patients are treated with L-dopa. We have studied [18F]dopa uptake in 6 patients with classic dopa-responsive dystonia (5 familial patients and 1 sporadic patient), aged 18 to 66 years. Data have been analyzed according to a graphic approach, calculating an influx constant for each region studied. We have also studied a seventh, clinically atypical, patient with juvenile dystonia-parkinsonism. Similar data have been calculated for a group of 10 healthy control subjects and 10 patients with Parkinson's disease. The 6 patients with typical dopa-responsive dystonia had a modest but significant reduction in the uptake of tracer into both caudate and putamen, which indicates a defect in the decarboxylation, vesicular uptake, and storage of [18F]dopa. This argues against the proposition that dopa-responsive dystonia is due to an inherited defect of tyrosine hydroxylase alone. In the atypical patient, however, we found a greater reduction of [18F]dopa uptake into both caudate and putamen, comparable with that in patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681782     DOI: 10.1002/ana.410300106

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

Review 1.  Dopa-responsive dystonia--clinical and genetic heterogeneity.

Authors:  Subhashie Wijemanne; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

2.  The usefulness of functional imaging in movement disorders: an illustrative case.

Authors:  K P Bhatia; N Turjanski; D J Brooks; C D Marsden; D Thrush
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

3.  Successful treatment of childhood onset symptomatic dystonia with levodopa.

Authors:  N A Fletcher; P D Thompson; J W Scadding; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

Review 4.  [Positron emission tomography in neuroscience. An integrative part of clinical diagnostic methods and experimental research].

Authors:  B Schaller
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

5.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

6.  A multidisciplinary study of patients with early-onset PD with and without parkin mutations.

Authors:  E Lohmann; S Thobois; S Lesage; E Broussolle; S Tezenas du Montcel; M-J Ribeiro; P Remy; A Pelissolo; B Dubois; L Mallet; P Pollak; Y Agid; A Brice
Journal:  Neurology       Date:  2008-11-05       Impact factor: 9.910

Review 7.  The role of astroglia on the survival of dopamine neurons.

Authors:  María Angeles Mena; Sonsoles de Bernardo; Maria José Casarejos; Santiago Canals; Eulalia Rodríguez-Martín
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

8.  Lessons from a remarkable family with dopa-responsive dystonia.

Authors:  G Harwood; R Hierons; N A Fletcher; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

Review 9.  Neuroimaging findings in children with paediatric neurotransmitter diseases.

Authors:  Wang-Tso Lee; Wen-Chin Weng; Shinn-Forng Peng; Kai-Yuan Tzen
Journal:  J Inherit Metab Dis       Date:  2009-05-20       Impact factor: 4.982

10.  Reply: Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.

Authors:  Niccolo E Mencacci; Alan M Pittman; Ioannis U Isaias; John Hardy; Stephan Klebe; Kailash P Bhatia; Nicholas W Wood
Journal:  Brain       Date:  2014-11-14       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.